Factores de riesgo cardiovascular

Bibliographische Referenzen

• Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M. Heart disease and stroke statistics 2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29-322.
• Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJL. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation. 2014;129(14):1483-92.
• Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372(14):1333-41.
• Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352(11):1138-45.
• Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM. Comparative determinants of 4 year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12): 1350.
• Dégano IR, Elosua R, Marrugat J. Epidemiología del síndrome coronario agudo en España: estimación del número de casos y la tendencia de 2005 a 2049. Revista Española de Cardiología. 2013; 66(6):472-81.
• Banegas JR, López García E, Dallongeville J, Guallar E, Halcox JP, Borghi C. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32(17):2143-52.
• Liu K, Daviglus ML, Loria CM, Colangelo LA, Spring B, Moller AC. Healthy lifestyle through young adulthood and the presence of low cardiovascular disease risk profile in middle age: the Coronary Artery Risk Development in (Young) Adults (CARDIA) study. Circulation. 2012;125(8):996-1004.
• Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet. 2004;364(9438):937-52.
• Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of c-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285(19):2481.
• Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41(3):279-81.
• Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G. Estimation of ten year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003.
• Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J. The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions. Circulation. 2006;114(25):2871-91.
• Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representa-tives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29): 2315-81.
• Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92(12):1752-9.
• Van Dis I, Geleijnse JM, Boer JM, Kromhout D, Boshuizen H, Grobbee DE. Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from The Netherlands. Eur J Prev Cardio-log. 2014;21(3):377-83.
• Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. [Calibrating the SCORE cardiovascular risk chart for use in Spain]. Rev Esp Cardiol. 2007;60(5):476-85.
• Nielsen S, Björck L, Berg J, Giang KW, Zverkova Sandström T, Falk K. Sex specific trends in 4 year survival in 37 276 men and women with acute myocardial infarction before the age of 55 years in Sweden, 1987-2006: a register based cohort study. BMJ Open. 2014;4(5):e004598.
• SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015;373(22): 2103-16.
• Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. 2011;171(5):404-10.
• Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delga-do V. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323.
• Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med. 2012;9(10):e1001321.
• Lind M, Svensson AM, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972-82.
• Cholesterol treatment trialists’ (CTT) collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90.
• Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta analysis of the relationship between non high density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53(4):316-22.
• McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case control study. Lancet. 2008;372(9634):224-33.
• Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL. Triglyceride rich lipoproteins and high density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345-61.
• Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-53.
• Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature based meta-analysis of prospective studies. J Intern Med. 2006;259(5):481-92.
• Van der A DL, Nooyens ACJ, van Duijnhoven FJB, Verschuren MMW, Boer JMA. All cause mortality risk of metabolically healthy abdominal obese individuals: the EPIC-MORGEN study. Obesity (Silver Spring). 2014;22(2):557-64.
• Romero Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368(9536):666-78.
• Schöttker B, Jorde R, Peasey A, Thorand B, Jansen EHJM, Groot L. Vitamin D and mortality: meta analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ. 2014;348:g3656.
• Sharalaya Z, Phelan D. Cardiac risk of extreme exercise. Sports Med Arthrosc Rev. 2019;27(1):e1-7.
• Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ. 1997;315(7114):973-80.
• Chow CK, Jolly S, Rao Melacini P, Fox KAA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010; 121(6):750-8.
• Banerjee A. A review of family history of cardiovascular disease: risk factor and research tool. Int J Clin Pract. 2012;66(6):536-43.
• Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2 stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33(9):2261-6.
• Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385(9984):2264-71.
• Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med.2012;367(14):1310-20.
• Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta analysis of 82 studies. Lancet. 2012;379(9822):1205-13.
• Martí Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8:CD006612.
• Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE. Association of estimated glomerular filtration rate and albuminuria with all cause and cardiovascular mortality in general population cohorts: a collaborative meta analysis. Lancet. 2010;375(9731):2073-81.
• Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85-97.
• Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK. EULAR evidence based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325-31.
• Maradit Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population based study. Arthritis Rheum. 2005;52(3):722-32.
• Giannelou M, Mavragani CP. Cardiovascular disease in systemic lupus erythematosus: A comprehensive update. J Autoimmun. 2017;82:1-12.
• Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B. Coronary Heart Disease in HIV Infected Individuals: JAIDS. J Acquir Immune Defic Syndr. 2003;33(4):506-12.
• Gonzaga C, Bertolami A, Bertolami M, Amodeo C, Calhoun D. Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens. 2015;29(12):705-12.
• Sorajja D, Gami AS, Somers VK, Behrenbeck TR, García Touchard A, López Jiménez F. Independent association between obstructive sleep apnea and subclinical coronary artery disease. Chest. 2008;133(4):927-33.
• Vlachopoulos CV, Terentes Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all cause mortality with erectile dysfunction: a systematic review and meta analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013;6(1):99-109.
• Russo R, Di Iorio B, Di Lullo L, Russo D. Epicardial adipose tissue: new parameter for cardiovascular risk assessment in high risk populations. J Nephrol. 2018;31(6):847-53.
• Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351(25):2611-8.
• Lorente Ros A, Monteagudo Ruiz JM, Rincón LM, Ortega Pérez R, Rivas S, Martínez Moya R. Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients. Cardiol J. 2020;27(5):489-96.
• Nasir K, Bittencourt MS, Blaha MJ, Blankstein R, Agatson AS, Rivera JJ. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66(15):1657-68.
• Haberl R, Becker A, Leber A, Knez A, Becker C, Lang C. Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. J Am Coll Cardiol. 2001;37(2):451-7.
• Van Werkhoven JM, Gaemperli O, Schuijf JD, Jukema JW, Kroft LJ, Leschka S. Multislice computed tomography coronary angiography for risk stratification in patients with an intermediate pretest likelihood. Heart. 2009;95(19):1607-11.
• Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium Score and Cardiovascular Risk.J Am Coll Cardiol. 2018 24;72(4):434–47.
• Den Ruijter HM, Peters SAE, Anderson TJ, Britton AR, Dekker JM, Ei-jkemans MJ. Common carotid intima media thickness measurements in cardiovascular risk prediction: a meta analysis. JAMA. 2012;308(8):796-803.
• Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all cause mortality with arterial stiffness: a systematic review and meta analysis. J Am Coll Cardiol. 2010;55(13):1318-27.
• Ankle Brachial Index Collaboration, Fowkes FGR, Murray GD, Butcher I, Heald CL, Lee RJ. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta analysis. JAMA. 2008;300(2):197-208.
• He FJ, Pombo Rodrigues S, MacGregor GA. Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality. BMJ Open. 2014;4(4):e004549.